142 related articles for article (PubMed ID: 19930738)
1. [Safety of the bivalent human papillomavirus vaccine--results following administration of more than 192,000 doses].
van der Maas NA; Kemmeren JM; de Melker HE
Ned Tijdschr Geneeskd; 2009; 153():A964. PubMed ID: 19930738
[TBL] [Abstract][Full Text] [Related]
2. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands.
van Klooster TM; Kemmeren JM; van der Maas NA; de Melker HE
Vaccine; 2011 Jun; 29(28):4601-7. PubMed ID: 21549785
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
Block SL; Brown DR; Chatterjee A; Gold MA; Sings HL; Meibohm A; Dana A; Haupt RM; Barr E; Tamms GM; Zhou H; Reisinger KS
Pediatr Infect Dis J; 2010 Feb; 29(2):95-101. PubMed ID: 19952863
[TBL] [Abstract][Full Text] [Related]
4. [Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands].
de Kok IM; Habbema JD; Mourits MJ; Coebergh JW; van Leeuwen FE
Ned Tijdschr Geneeskd; 2008 Sep; 152(37):2001-4. PubMed ID: 18825885
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus vaccine: a paradigm shift for pediatricians.
Jenson HB
Curr Opin Pediatr; 2009 Feb; 21(1):112-21. PubMed ID: 19242247
[TBL] [Abstract][Full Text] [Related]
6. [Advisory report from the Health Council of the Netherlands to include human papillomavirus vaccination in the national immunisation programme for the prevention of cervical cancer].
Boeke AJ
Ned Tijdschr Geneeskd; 2008 Apr; 152(17):981-3. PubMed ID: 18549170
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events.
Callréus T; Svanström H; Nielsen NM; Poulsen S; Valentiner-Branth P; Hviid A
Vaccine; 2009 May; 27(22):2954-8. PubMed ID: 19428906
[TBL] [Abstract][Full Text] [Related]
8. HPV vaccination: vaccine acceptance, side effects and screening intentions.
Paul-Ebhohimhen V; Huc S; Tissington H; Oates K; Stark C
Community Pract; 2010 Jun; 83(6):30-3. PubMed ID: 20586376
[TBL] [Abstract][Full Text] [Related]
9. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
Dunne EF; Datta SD; E Markowitz L
Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
[TBL] [Abstract][Full Text] [Related]
10. Girls' preferences for HPV vaccination: a discrete choice experiment.
de Bekker-Grob EW; Hofman R; Donkers B; van Ballegooijen M; Helmerhorst TJ; Raat H; Korfage IJ
Vaccine; 2010 Sep; 28(41):6692-7. PubMed ID: 20708696
[TBL] [Abstract][Full Text] [Related]
11. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG
Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049
[TBL] [Abstract][Full Text] [Related]
12. [Human papillomavirus vaccines].
Brun JL
J Gynecol Obstet Biol Reprod (Paris); 2008 Feb; 37 Suppl 1():S155-66. PubMed ID: 18187268
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus vaccines: an update for gynecologists.
Ault KA
Clin Obstet Gynecol; 2008 Sep; 51(3):527-32. PubMed ID: 18677145
[TBL] [Abstract][Full Text] [Related]
14. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
15. Parental acceptance of Human Papillomavirus vaccines.
Lenselink CH; Gerrits MM; Melchers WJ; Massuger LF; van Hamont D; Bekkers RL
Eur J Obstet Gynecol Reprod Biol; 2008 Mar; 137(1):103-7. PubMed ID: 17368910
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
[TBL] [Abstract][Full Text] [Related]
17. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia.
Watson M; Shaw D; Molchanoff L; McInnes C
Aust N Z J Public Health; 2009 Aug; 33(4):365-70. PubMed ID: 19689598
[TBL] [Abstract][Full Text] [Related]
18. [HPV vaccine and cervical cancer prevention in general practice. Survey conducted among general practitioners in the French departments of Eure-et-Loir and Cher].
Pélissier G; Bastides F
Rev Prat; 2008 Dec; 58(19 Suppl):25-31. PubMed ID: 19253788
[TBL] [Abstract][Full Text] [Related]
19. [Reasons not to have your daughter vaccinated against the human papilloma virus in Twente: a questionnaire study].
van der Berg JD; Roorda J; Westerman MJ
Ned Tijdschr Geneeskd; 2010; 154():A1923. PubMed ID: 20699020
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic human papillomavirus vaccination: a breakthrough in primary cervical cancer prevention.
Garcia FA; Saslow D
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):761-81, ix. PubMed ID: 18061868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
